Market News

Gilead Sciences (GILD)

Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order by an Indian Patent Office that rejected two patent claims for its best seller drug Viread (tenofovir disoproxil fumarate).
In August, the Indian Patent Office in Delhi rejected two patents sought by the firm for Viread after patient groups and Indian company Cipla challenged its patentability.

Dec 8 · 3:14:00 PM · Source: The Economic Times
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and Pfizer announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopaedic surgery in the first half of 2010.
The application will be supported by ADVANCE-2 and ADVANCE-3, two clinical trials that evaluated apixaban versus the European dosing regimen of for prevention of VTE in patients undergoing orthopaedic surgery.

Dec 7 · 4:26:00 PM · Source: Pharmabiz.com · Related: Pfizer
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Amgen (AMGN)

Amgen announced that its Board of Directors has authorized repurchases of up to an additional $5 billion in Amgen common stock.
Amgen currently has approximately $1.2 billion remaining under its previous stock repurchase authorization.

Dec 7 · 4:07:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Abbott Labs (ABT)

Abbott’s Ibis technology for detecting and characterizing a vast array of microorganisms has been named one of the top innovations in 2009 by The Scientist magazine.
Abbott’s Ibis system (now marketed under the PLEX ID trade name) was recognized for the honor, in part, because it is designed to detect and characterize a broad range of microorganisms in a given sample, including viruses, bacteria and fungi.

Dec 7 · 2:51:00 PM · Source: PR USA
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Pfizer (PFE)

Pfizer said Tuesday it had reached an agreement to license the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix, an Israeli biotechnology company.
This deal would put Pfizer into competition with Cerezyme, Genzyme’s biggest-selling product.

Dec 1 · 12:32:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Covidien Ltd. (COV)

Covidien, a medical device company, said Tuesday that it posted net profit of $56 million, or 11 cents a share, for the fiscal fourth quarter ended Sept. 25, compared with $409 million, or 84 cents a share, a year earlier. Net results were reduced by a variety of charges related to various divestitures and acquisitions.

Nov 17 · 12:09:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb will continue to pursue acquisitions, the drug maker's financial chief said, with its war chest bolstered this week by a $1.75 billion cash infusion from a debt refinancing by its Mead Johnson Nutrition Co. (MJN).
By the end of this year, Bristol-Myers expects to have gross cash of more than $10 billion and more than $2 billion in net cash, factoring in the company's debt,

Nov 14 · 4:07:00 PM · Source: The Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Cadence Pharmaceuticals Inc. (CADX)

Cadence Pharmaceuticals, said Friday the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months. The extended PDUFA goal date is February 12, 2010.
The company said it remains confident in its NDA submission and will continue to work closely with the FDA toward the potential approval of intravenous acetaminophen, noting it is now planning for a launch early in the second quarter of 2010.

Nov 13 · 11:34:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Previous · Next